Drawing for ABSIEVE

USPTO serial 86970797

ABSIEVE

Reviewed by CopyMark Law Group

Reg. 5263476Status 702Renewal
Filing date
Status date
Registration date
Aug 15, 2017
Examiner
O'ROURKE, JONATHAN RYAN
Law office
Historical data usage

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with ABSIEVE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*

Plus Government fees of $650

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Karen L. Elbing

Karen L. Elbing CLARK & ELBING LLP101 FEDERAL STREET, 15TH FLOORBOSTON, MA 02110United States

Goods and services

ClassDescriptionStatusFirst use
042Scientific and technological services and research projects for the preparation of peptide and antibody libraries, and for identification and characterization of binding molecules, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services and research projects for the preparation, identification and characterisation of peptides and antibodies, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services and research projects for the preparation and identification of recombinant antibodies, single-chain antibodies, diabodies, tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, and antibody fragments, in particular Fab and scFv fragments, and of nucleic acid sequences coding for these molecules, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services and research projects in relation to antibody discovery, namely, scientific research and analysis in the field of antibody research and drug design; scientific and technological services and research projects in relation to screening of natural, engineered and immunized libraries, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services and research projects in relation to screening of antibody libraries, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services and research projects in relation to phage display, phage panning and yeast display vectors, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services and research projects in relation to next-generation yeast display and antibody selection process, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services and research projects in relation to the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services in relation to drug discovery by high throughput screen and antibody delivery for therapeutic application, namely, scientific research and analysis in the field of antibody research and drug designACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 15, 2026REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Feb 12, 2025NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Feb 12, 2025C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Aug 26, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Feb 8, 2024E815TEAS SECTION 8 & 15 RECEIVED—
Aug 15, 2022REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Aug 15, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 30, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 30, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 10, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 25, 2017PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Apr 17, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 13, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 12, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 12, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 16, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 16, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 16, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 17, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 17, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 16, 2017ALIEASSIGNED TO LIE—
Feb 1, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 2, 2016GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 2, 2016GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 2, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 29, 2016AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Jul 29, 2016PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jul 26, 2016DOCKASSIGNED TO EXAMINER—
Apr 15, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 14, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance